Lachlan MacKinnon (L) and Adrian Woolfson (Replay)

With AAV al­ter­na­tive and DNA writ­ing tech, a new hub-and-spoke start­up wants to ‘de­moc­ra­tize’ gene ther­a­pies

When Adri­an Woolf­son was head of R&D at Sang­amo, he be­gan con­tem­plat­ing start­ing his own com­pa­ny. His goal? Solve some of the key chal­lenges plagu­ing ge­nom­ic med­i­cine he’d seen while work­ing on a wide spec­trum of Sang­amo’s pro­grams.

Then, he met Lach­lan MacK­in­non, a biotech in­vestor, in Lon­don, and the two re­al­ized they shared a sim­i­lar vi­sion, de­spite their “or­thog­o­nal” back­grounds, he told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.